Effrosyni D. Manali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Effrosyni D. Manali has a total of 368 co-authors. Here are the top co-authors by number of shared publications:
- Ioannis Tomos
Pulmonary Department, “Sotiria” Athens Hospital for Thoracic Diseases, 11527 Athens, Greece
10 shared publications Spyros Papiris
2nd Pulmonary Medicine Department, General University Hospital "Attikon", Medical School, National and Kapodistrian University of Athens, Greece , Athens , Greece
10 shared publications- Demosthenes Bouros
Pneumonology Department Athens Medical Center Athens Greece
9 shared publications Spyridon Papiris
2nd Respiratory Medicine Department, “Attikon” University Hospital, Chaidari (Athens), Greece
8 shared publicationsSpyros A. Papiris
Athens Medical School, National and Kapodistrian University of Athens, Attica, Greece
8 shared publications- Anna Karakatsani
National and Kapodistrian University of Athens, "ATTIKON" University Hospital, Haidari, Athens, Greece
6 shared publications
Latest Publications
- 28 October 2026
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
Lymphangioleiomyomatosis: From Genetics to Management
Lymphangioleiomyomatosis (LAM) is a rare multisystem disease that exemplifies how sustained investigation can transform both biological understanding and clinical management. LAM is diagnosed almost exclusively in women, typically during the reproductive years, consistent with an important role for hormonal influences in disease activity. The disease is characterized by diffuse cystic lung remodeling that can lead to progressive loss of lung function and, in severe cases, respiratory failure. Once viewed primarily as an unusual smooth muscle-like proliferation, LAM is now considered a low-grade metastasizing neoplasm characterized by heterogeneous disease-cell states that contribute to remodeling of the lung parenchyma and interact dynamically with stromal, lymphatic, immune, metabolic, and hormonal cues. Although the anatomical origin of LAM cells remains debated and continues to be an active area of research, sporadic and tuberous sclerosis complex-associated LAM (S-LAM and TSC-LAM, respectively) share a central molecular mechanism: biallelic inactivation of TSC1 or TSC2, which disrupts the TSC1-TSC2 protein complex and results in constitutive activation of mechanistic target of rapamycin complex 1 (mTORC1). This mechanistic insight provided the rationale for mTORC1 inhibition with sirolimus, which has transformed disease management by stabilizing lung function and reducing disease burden in many patients. In parallel, serum vascular endothelial growth factor-D has emerged as a clinically useful biomarker supporting noninvasive diagnosis and the assessment of disease burden and treatment response. Yet current therapies are not curative, and LAM cells persist despite mTORC1 inhibition. Continued advances in single-cell biology, genomic studies, hormonal and metabolic regulation, mechanistic dissection of disease-cell states, immune-stromal interactions, and biomarker discovery are now reshaping LAM as a model of precision medicine for rare neoplastic diseases. These efforts may guide rational combination therapies aimed not only at controlling disease progression but also, ultimately, at eliminating persistent LAM cells.
- 28 October 2026
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
Lymphangioleiomyomatosis: From Genetics to Management
Lymphangioleiomyomatosis (LAM) is a rare multisystem disease that exemplifies how sustained investigation can transform both biological understanding and clinical management. LAM is diagnosed almost exclusively in women, typically during the reproductive years, consistent with an important role for hormonal influences in disease activity. The disease is characterized by diffuse cystic lung remodeling that can lead to progressive loss of lung function and, in severe cases, respiratory failure. Once viewed primarily as an unusual smooth muscle-like proliferation, LAM is now considered a low-grade metastasizing neoplasm characterized by heterogeneous disease-cell states that contribute to remodeling of the lung parenchyma and interact dynamically with stromal, lymphatic, immune, metabolic, and hormonal cues. Although the anatomical origin of LAM cells remains debated and continues to be an active area of research, sporadic and tuberous sclerosis complex-associated LAM (S-LAM and TSC-LAM, respectively) share a central molecular mechanism: biallelic inactivation of TSC1 or TSC2, which disrupts the TSC1-TSC2 protein complex and results in constitutive activation of mechanistic target of rapamycin complex 1 (mTORC1). This mechanistic insight provided the rationale for mTORC1 inhibition with sirolimus, which has transformed disease management by stabilizing lung function and reducing disease burden in many patients. In parallel, serum vascular endothelial growth factor-D has emerged as a clinically useful biomarker supporting noninvasive diagnosis and the assessment of disease burden and treatment response. Yet current therapies are not curative, and LAM cells persist despite mTORC1 inhibition. Continued advances in single-cell biology, genomic studies, hormonal and metabolic regulation, mechanistic dissection of disease-cell states, immune-stromal interactions, and biomarker discovery are now reshaping LAM as a model of precision medicine for rare neoplastic diseases. These efforts may guide rational combination therapies aimed not only at controlling disease progression but also, ultimately, at eliminating persistent LAM cells.
- Open Access
- 6 October 2026
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
Pediatric-to-Adult Transition of Care in Patients with Surfactant Metabolism Disorders
Genetic disorders of surfactant metabolism, caused by pathogenic variants in the surfactant-related genes (SRGs) SFTPB, ABCA3, SFTPC, and NKX2-1, were long considered diseases of the neonate and the infant, with an outcome measured in weeks or months. Advances in neonatal intensive care, increased awareness, earlier molecular diagnosis, structured management, and pediatric lung transplantation have generated a growing population of adolescents and young adults living with a surfactant metabolism disorder. In the largest European survey of childhood interstitial lung disease (chILD) survivors, surfactant-related disorders accounted for about one in five patients now followed in adult centers. These patients must leave pediatric services that have often known them for many years, entering adult respiratory care systems, which are primarily around fibrotic lung disease of older adults: a setting where SRG diseases are rarely recognized. No literature is specifically devoted to transition in surfactant metabolism disorders. Therefore, this review brings together three bodies of evidence: the pediatric natural history of SFTPB, ABCA3, SFTPC, and NKX2-1-related disorders; specificities of SRG ILD surviving into and/or presenting in adulthood; the general principles of transition in rare disease, including the recent European Respiratory Society (ERS) statement on transition of care in chILD and what each implies for this group. Finally, the patient and family perspective was discussed, based on very sparse qualitative research. A proposed framework and a research agenda were suggested.
- 6 October 2026
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
Open AccessPediatric-to-Adult Transition of Care in Patients with Surfactant Metabolism Disorders
Genetic disorders of surfactant metabolism, caused by pathogenic variants in the surfactant-related genes (SRGs) SFTPB, ABCA3, SFTPC, and NKX2-1, were long considered diseases of the neonate and the infant, with an outcome measured in weeks or months. Advances in neonatal intensive care, increased awareness, earlier molecular diagnosis, structured management, and pediatric lung transplantation have generated a growing population of adolescents and young adults living with a surfactant metabolism disorder. In the largest European survey of childhood interstitial lung disease (chILD) survivors, surfactant-related disorders accounted for about one in five patients now followed in adult centers. These patients must leave pediatric services that have often known them for many years, entering adult respiratory care systems, which are primarily around fibrotic lung disease of older adults: a setting where SRG diseases are rarely recognized. No literature is specifically devoted to transition in surfactant metabolism disorders. Therefore, this review brings together three bodies of evidence: the pediatric natural history of SFTPB, ABCA3, SFTPC, and NKX2-1-related disorders; specificities of SRG ILD surviving into and/or presenting in adulthood; the general principles of transition in rare disease, including the recent European Respiratory Society (ERS) statement on transition of care in chILD and what each implies for this group. Finally, the patient and family perspective was discussed, based on very sparse qualitative research. A proposed framework and a research agenda were suggested.
- 15 July 2026
- Published by Wiley in Respirology
- Vol. 31 (10) , 1014-1028
Pulmonary Alveolar Proteinosis in Greece–Türkiye–Cyprus: Answers in a Real‐Life Comparison
Background and Objective: Pulmonary alveolar proteinosis (PAP) is a rare disease of inappropriate alveolar surfactant accumulation. The study objective was to compare Greece–Türkiye–Cyprus cohorts, followed‐up for 20 years. Methods: Data were retrieved retrospectively by chart review. Results: One hundred and thirty patients, Greece 39, Türkiye 87, Cyprus 4, were included; 115 (89%) autoimmune (a)PAP, 13 (10%) secondary, 1 (1%) hereditary. Abnormal anti‐GM‐CSF antibody titre was available in 86/115 patients, further analyzed for aPAP. Forty (46%) were male, with median (IQR) age at diagnosis of 40 (31–50) years. At median (IQR) duration of clinical follow‐up of 39 (18–78) months, three patients died. Non‐survivors had higher rates of cardiovascular disease [67% vs. 5%, p < 0.001], LTOT (67% vs. 13%, p = 0.001), pulmonary fibrosis [67% vs. 5%] and worse functional status at follow‐up [FVC% pred 49 (29) vs. 87 (74–97); p = 0.026, DLCO% pred 21 (46) vs. 72 (58–82); p = 0.016]. aPAP patients were stratified by therapy group (no WLL‐no i‐GM‐CSF, WLL alone, i‐GMCSF alone and both WLL and iGM‐CSF). WLL was more frequently performed in Türkiye and i‐GMCSF alone in Greece ( p = 0.006). All therapies were effective. No difference was detected on outcome when sole iGM‐CSF was compared to WLL alone or in combination with iGM‐CSF [deceased/alive 0%/100% vs. 7%/93%, p = 0.491]. Sole iGM‐CSF significantly ameliorated clinical and functional parameters of disease severity [DLCO% ( p = 0.013), SatO 2 ( p = 0.002), 6MWT ( p = 0.026)]. Across all therapy groups, pulmonary fibrosis eliminated beneficial response to treatment. Conclusion: This first real‐life comparison of aPAP cohorts originating from three countries showed the non‐inferiority of sole iGM‐CSF treatment. Fibrosis negatively affects response to treatment and survival.
- 15 July 2026
- Published by Wiley in Respirology
- Vol. 31 (10) , 1014-1028
Pulmonary Alveolar Proteinosis in Greece–Türkiye–Cyprus: Answers in a Real‐Life Comparison
Background and Objective: Pulmonary alveolar proteinosis (PAP) is a rare disease of inappropriate alveolar surfactant accumulation. The study objective was to compare Greece–Türkiye–Cyprus cohorts, followed‐up for 20 years. Methods: Data were retrieved retrospectively by chart review. Results: One hundred and thirty patients, Greece 39, Türkiye 87, Cyprus 4, were included; 115 (89%) autoimmune (a)PAP, 13 (10%) secondary, 1 (1%) hereditary. Abnormal anti‐GM‐CSF antibody titre was available in 86/115 patients, further analyzed for aPAP. Forty (46%) were male, with median (IQR) age at diagnosis of 40 (31–50) years. At median (IQR) duration of clinical follow‐up of 39 (18–78) months, three patients died. Non‐survivors had higher rates of cardiovascular disease [67% vs. 5%, p < 0.001], LTOT (67% vs. 13%, p = 0.001), pulmonary fibrosis [67% vs. 5%] and worse functional status at follow‐up [FVC% pred 49 (29) vs. 87 (74–97); p = 0.026, DLCO% pred 21 (46) vs. 72 (58–82); p = 0.016]. aPAP patients were stratified by therapy group (no WLL‐no i‐GM‐CSF, WLL alone, i‐GMCSF alone and both WLL and iGM‐CSF). WLL was more frequently performed in Türkiye and i‐GMCSF alone in Greece ( p = 0.006). All therapies were effective. No difference was detected on outcome when sole iGM‐CSF was compared to WLL alone or in combination with iGM‐CSF [deceased/alive 0%/100% vs. 7%/93%, p = 0.491]. Sole iGM‐CSF significantly ameliorated clinical and functional parameters of disease severity [DLCO% ( p = 0.013), SatO 2 ( p = 0.002), 6MWT ( p = 0.026)]. Across all therapy groups, pulmonary fibrosis eliminated beneficial response to treatment. Conclusion: This first real‐life comparison of aPAP cohorts originating from three countries showed the non‐inferiority of sole iGM‐CSF treatment. Fibrosis negatively affects response to treatment and survival.
- Open Access
- 26 March 2025
- Published by Wiley in Respirology
- Vol. 30 (6) , 523-532
Impact of A Multidisciplinary Team Discussion for Genetic Lung Fibrosis
Background and Objective: Approximately 30% of individuals diagnosed with familial pulmonary fibrosis (FPF) exhibit a pathogenic variant upon genetic analysis. We established a genetic Multidisciplinary Discussion (geneMDD) aimed to enhance expertise in diagnosing and managing FPF. This study aimed at prospectively evaluating the impact of geneMDD on diagnosis and treatment in patients referred to geneMDD.Methods: In this prospective study, we enrolled all consecutive patients referred to the geneMDD. At each meeting, the impact of the meeting was questioned on the genetic conclusion, the pulmonary diagnosis, and the treatment.Results: A total of 115 patients were included. Before geneMDD, rare variants were detected in 82 out of 107 patients, among which 65 variants were classified as pathogenic/likely pathogenic. Following geneMDD, 2 pathogenic variants (3%) were reclassified as variants of uncertain significance (VUS) (n = 1) or benign (n = 1). Among the 17 variants initially classified as VUS, 2 (11.8%) were reclassified as likely pathogenic/pathogenic. The pulmonary diagnosis was confirmed for all patients (unclassifiable lung fibrosis was the more frequent diagnosis, n = 38, 33.0%). The therapeutic regimen was changed after geneMDD in 30 patients. Factors associated with therapeutic changes included the pulmonary diagnosis and presence of a pathogenic/likely pathogenic variant. In addition, the French health system allows offering whole genome sequencing (WGS) in patients with a first negative genetic analysis by NGS panel after discussion in geneMDD, but in total, since September 1st, 2021, WGS was negative for the four analysed families.Conclusion: This study suggests that geneMDD could influence the treatment of FPF patients.
- 26 March 2025
- Published by Wiley in Respirology
- Vol. 30 (6) , 523-532
Open AccessImpact of A Multidisciplinary Team Discussion for Genetic Lung Fibrosis
Background and Objective: Approximately 30% of individuals diagnosed with familial pulmonary fibrosis (FPF) exhibit a pathogenic variant upon genetic analysis. We established a genetic Multidisciplinary Discussion (geneMDD) aimed to enhance expertise in diagnosing and managing FPF. This study aimed at prospectively evaluating the impact of geneMDD on diagnosis and treatment in patients referred to geneMDD.Methods: In this prospective study, we enrolled all consecutive patients referred to the geneMDD. At each meeting, the impact of the meeting was questioned on the genetic conclusion, the pulmonary diagnosis, and the treatment.Results: A total of 115 patients were included. Before geneMDD, rare variants were detected in 82 out of 107 patients, among which 65 variants were classified as pathogenic/likely pathogenic. Following geneMDD, 2 pathogenic variants (3%) were reclassified as variants of uncertain significance (VUS) (n = 1) or benign (n = 1). Among the 17 variants initially classified as VUS, 2 (11.8%) were reclassified as likely pathogenic/pathogenic. The pulmonary diagnosis was confirmed for all patients (unclassifiable lung fibrosis was the more frequent diagnosis, n = 38, 33.0%). The therapeutic regimen was changed after geneMDD in 30 patients. Factors associated with therapeutic changes included the pulmonary diagnosis and presence of a pathogenic/likely pathogenic variant. In addition, the French health system allows offering whole genome sequencing (WGS) in patients with a first negative genetic analysis by NGS panel after discussion in geneMDD, but in total, since September 1st, 2021, WGS was negative for the four analysed families.Conclusion: This study suggests that geneMDD could influence the treatment of FPF patients.
- 17 January 2022
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 52 (5) , e13742
Peripheral blood natural killer cells in sarcoidosis are associated with early cardiac involvement
Aim: To evaluate the distribution of circulating immune cell subsets in peripheral blood of patients with sarcoidosis and investigate if there is an association with an underlying cardiac involvement.Methods and results: Eighty‐five newly diagnosed treatment‐naïve patients with sarcoidosis (50 women) were included in the study. All patients underwent a thorough cardiac investigation, including cardiac magnetic resonance imaging (CMR). Of all patients, 19 (23.53%) had myocardial involvement, and the NK subpopulation in these patients in peripheral blood was significantly decreased compared to patients without (n = 63, p = 0.001 and p = 0.003 respectively). The absolute number of NKT cells (CD3+CD16/56+) in patients with cardiac involvement was highly correlated with T2 map increased values in MRI (r = −686, p = 0.041) showing that low NKT cell count correlates with the inflammatory process of the heart. No difference in CD19, CD3, CD4, CD8 and CD3−NK cell counts was found between groups. Lung severity was not found to correlate with the number of NK cells.Conclusion: We found that low NK cell count in peripheral blood of patients with sarcoidosis is associated with cardiac involvement, and the number of NK‐T cells correlates with CMR findings indicative of myocardial inflammation. This finding might have a potential clinical application in detecting clinically silent cardiac involvement in sarcoidosis and may also suggest potential targets for therapeutic interventions.
- 17 January 2022
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 52 (5) , e13742
Peripheral blood natural killer cells in sarcoidosis are associated with early cardiac involvement
Aim: To evaluate the distribution of circulating immune cell subsets in peripheral blood of patients with sarcoidosis and investigate if there is an association with an underlying cardiac involvement.Methods and results: Eighty‐five newly diagnosed treatment‐naïve patients with sarcoidosis (50 women) were included in the study. All patients underwent a thorough cardiac investigation, including cardiac magnetic resonance imaging (CMR). Of all patients, 19 (23.53%) had myocardial involvement, and the NK subpopulation in these patients in peripheral blood was significantly decreased compared to patients without (n = 63, p = 0.001 and p = 0.003 respectively). The absolute number of NKT cells (CD3+CD16/56+) in patients with cardiac involvement was highly correlated with T2 map increased values in MRI (r = −686, p = 0.041) showing that low NKT cell count correlates with the inflammatory process of the heart. No difference in CD19, CD3, CD4, CD8 and CD3−NK cell counts was found between groups. Lung severity was not found to correlate with the number of NK cells.Conclusion: We found that low NK cell count in peripheral blood of patients with sarcoidosis is associated with cardiac involvement, and the number of NK‐T cells correlates with CMR findings indicative of myocardial inflammation. This finding might have a potential clinical application in detecting clinically silent cardiac involvement in sarcoidosis and may also suggest potential targets for therapeutic interventions.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA3478
COVID-19: the day after
Introduction: Patients recovering from pneumonia and ARDS may develop fibrotic changes. Concerning COVID-19, there is evidence that residual persistent ground glass opacities and/or reticular infiltrates could be related with the development of diffuse parenchymal lung disease. Aim: The detection of interstitial lung disease post COVID-19 pneumonia. Methods: Patients were prospectively assessed 3 months after hospital discharge with high resolution computerized tomography of the chest (HRCT), pulmonary lung function tests (PFTs), SpO2, 6minute walk test (6MWT) and Saint George Respiratory Questionnaire (SGRQ). Patients were classified according to acute phase pneumonia extent as: mild (50%). Results: 23 patients (6 women, mean age 55 yrs) were included. 2 patients had a history of mechanical ventilation and 3 of pulmonary embolism. Mild (8), moderate (9) and severe (6) disease patients had no significant differences in age, gender and smoking history. Fifteen (65%) had at least one comorbidity including chronic obstructive respiratory disease. At 3 months patients presented mean values (SD) of FEV1%pred of 98,4±20,3, FVC%pred 104,3±18,3, DLCO%pred 89,2±10,3, Sp02 97,7±0,7%, 6MWT 571,4±87m and SGRQ 4,56(0-8,14). Follow-up HRCT was evaluated as normal or near-normal in all with no significant differences among the three severity groups. 20 patients had normal PFTs, 2 an obstructive pattern (underlying lung disease) and 1 a restrictive pattern with normal DLCO. Conclusion: The results of the present study do not support the hypothesis of the development of diffuse parenchymal lung disease after COVID-19 pneumonia in this study group. The study is ongoing.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA3478
COVID-19: the day after
Introduction: Patients recovering from pneumonia and ARDS may develop fibrotic changes. Concerning COVID-19, there is evidence that residual persistent ground glass opacities and/or reticular infiltrates could be related with the development of diffuse parenchymal lung disease. Aim: The detection of interstitial lung disease post COVID-19 pneumonia. Methods: Patients were prospectively assessed 3 months after hospital discharge with high resolution computerized tomography of the chest (HRCT), pulmonary lung function tests (PFTs), SpO2, 6minute walk test (6MWT) and Saint George Respiratory Questionnaire (SGRQ). Patients were classified according to acute phase pneumonia extent as: mild (50%). Results: 23 patients (6 women, mean age 55 yrs) were included. 2 patients had a history of mechanical ventilation and 3 of pulmonary embolism. Mild (8), moderate (9) and severe (6) disease patients had no significant differences in age, gender and smoking history. Fifteen (65%) had at least one comorbidity including chronic obstructive respiratory disease. At 3 months patients presented mean values (SD) of FEV1%pred of 98,4±20,3, FVC%pred 104,3±18,3, DLCO%pred 89,2±10,3, Sp02 97,7±0,7%, 6MWT 571,4±87m and SGRQ 4,56(0-8,14). Follow-up HRCT was evaluated as normal or near-normal in all with no significant differences among the three severity groups. 20 patients had normal PFTs, 2 an obstructive pattern (underlying lung disease) and 1 a restrictive pattern with normal DLCO. Conclusion: The results of the present study do not support the hypothesis of the development of diffuse parenchymal lung disease after COVID-19 pneumonia in this study group. The study is ongoing.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 446
Telomere-Related Gene mutations in a Greek cohort of suspected monogenic pulmonary fibrosis patients
Background: Telomere-related genes (TRG) mutations are detected in 30% of familial pulmonary fibrosis (FPF) and are also associated with personal/familial extra-pulmonary disease suggestive of short telomere syndrome (STS). Aim: to evaluate the prevalence of TRG mutations in a national cohort of interstitial lung disease (ILD) with suspected genetic predisposition in Greece and to define patients’ characteristics and impact on outcome.Methods: Genetic diagnoses made between December 2014-September 2019 in patients with FPF, pulmonary fibrosis at young age or personal and/or family extra-pulmonary disease suggestive of STS were analyzed. Results: 150 ILD patients, 73% male, age-at-diagnosis 67 years old, 33% non-smokers, 75% with definite/probable UIP or CPFE, 93% with dyspnea/cough, FVC% pred 75%, DLCO% pred 49% were tested; FPF was 65%, 19% young age, 21% personal and 17% family extra-pulmonary disease suggestive of STS; 21% were tested for more than 1 indication. TRG pathogenic variations were detected in 19 (13%): 13 in a familial, 3 in young age and 3 in extra-pulmonary disease suggestive of STS context as follows: TERT, TERC, RTEL1, PARN, NOP10, NHP2 in 8,5,2,2,1 and 1 respectively. No difference was detected in epidemiological-clinical-radiologic-functional characteristics between patients without and with mutations apart from age-at-diagnosis [69 vs 62 years, p<0.001)]. Patients with TRG mutations were deceased at a younger age compared to those without (70 vs 76 years respectively, p=0.045). GAP index was the only independent factor of survival (p=0.029).Conclusion: TRG mutations were detected in 13% of patients tested. TERT and TERC mutations were the most frequent.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 446
Telomere-Related Gene mutations in a Greek cohort of suspected monogenic pulmonary fibrosis patients
Background: Telomere-related genes (TRG) mutations are detected in 30% of familial pulmonary fibrosis (FPF) and are also associated with personal/familial extra-pulmonary disease suggestive of short telomere syndrome (STS). Aim: to evaluate the prevalence of TRG mutations in a national cohort of interstitial lung disease (ILD) with suspected genetic predisposition in Greece and to define patients’ characteristics and impact on outcome.Methods: Genetic diagnoses made between December 2014-September 2019 in patients with FPF, pulmonary fibrosis at young age or personal and/or family extra-pulmonary disease suggestive of STS were analyzed. Results: 150 ILD patients, 73% male, age-at-diagnosis 67 years old, 33% non-smokers, 75% with definite/probable UIP or CPFE, 93% with dyspnea/cough, FVC% pred 75%, DLCO% pred 49% were tested; FPF was 65%, 19% young age, 21% personal and 17% family extra-pulmonary disease suggestive of STS; 21% were tested for more than 1 indication. TRG pathogenic variations were detected in 19 (13%): 13 in a familial, 3 in young age and 3 in extra-pulmonary disease suggestive of STS context as follows: TERT, TERC, RTEL1, PARN, NOP10, NHP2 in 8,5,2,2,1 and 1 respectively. No difference was detected in epidemiological-clinical-radiologic-functional characteristics between patients without and with mutations apart from age-at-diagnosis [69 vs 62 years, p<0.001)]. Patients with TRG mutations were deceased at a younger age compared to those without (70 vs 76 years respectively, p=0.045). GAP index was the only independent factor of survival (p=0.029).Conclusion: TRG mutations were detected in 13% of patients tested. TERT and TERC mutations were the most frequent.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 3190
Devise use errors among patients with asthma and COPD-A real-life study
Background: Incorrect use of inhaler devices is associated with unfavorable outcomes Aim: To evaluate device use errors in asthma and COPD patients treated in outpatient clinics of 3 tertiary hospitals and one private practice office in Greece Methods: Demographics and medical history were recorded. Patients demonstrated the use of their prescribed device and use was evaluated according to predefined steps Results: 607 patients (50.2%male, mean age 60.2years) performed 663 demonstrations (56 patients were using 2 different types of devices). 49.8% were treated for asthma and 50.2% for COPD. 79.5% were using DPIs. Errors were documented in 41.2%, were associated with the type of device, p<0.001 and were less common in asthmatics compared to COPD patients 63.3% vs 54.5% respectively, p=0.013. Errors were more common among patients using pMDIs compared to those using DPIs (48.5% vs 39.1%, respectively p=0.020) and was associated with more exacerbations in the previous year (1.48±1.3 vs 0.82±1.00, for incorrect and correct use respectively, p<0.001). The commonest error in both pMDIs and DPIs was associated with the breathing in maneuver, 52% and 48.3% respectively. 15.5% of patients were never trained. Trained patients performed less errors compared to not trained patients, 14.6% vs 66.9% respectively, p<0.001. Correct use was more common among those trained by a doctor compared to other health care professionals 75.2% vs 26.5% respectively, p<0.001 Conclusion: Device use errors are common and associated with unfavorable outcomes. Trained patients were more likely to use the device correctly. Patients should be encouraged to demonstrate the use of their devices during medical visits in everyday clinical practice
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 3190
Devise use errors among patients with asthma and COPD-A real-life study
Background: Incorrect use of inhaler devices is associated with unfavorable outcomes Aim: To evaluate device use errors in asthma and COPD patients treated in outpatient clinics of 3 tertiary hospitals and one private practice office in Greece Methods: Demographics and medical history were recorded. Patients demonstrated the use of their prescribed device and use was evaluated according to predefined steps Results: 607 patients (50.2%male, mean age 60.2years) performed 663 demonstrations (56 patients were using 2 different types of devices). 49.8% were treated for asthma and 50.2% for COPD. 79.5% were using DPIs. Errors were documented in 41.2%, were associated with the type of device, p<0.001 and were less common in asthmatics compared to COPD patients 63.3% vs 54.5% respectively, p=0.013. Errors were more common among patients using pMDIs compared to those using DPIs (48.5% vs 39.1%, respectively p=0.020) and was associated with more exacerbations in the previous year (1.48±1.3 vs 0.82±1.00, for incorrect and correct use respectively, p<0.001). The commonest error in both pMDIs and DPIs was associated with the breathing in maneuver, 52% and 48.3% respectively. 15.5% of patients were never trained. Trained patients performed less errors compared to not trained patients, 14.6% vs 66.9% respectively, p<0.001. Correct use was more common among those trained by a doctor compared to other health care professionals 75.2% vs 26.5% respectively, p<0.001 Conclusion: Device use errors are common and associated with unfavorable outcomes. Trained patients were more likely to use the device correctly. Patients should be encouraged to demonstrate the use of their devices during medical visits in everyday clinical practice
- Open Access
- 7 April 2020
- Published by S. Karger AG in Kompass Pneumologie
- Vol. 8 (2) , 68-75
Idiopathische Lungenfibrose: Best Practices für das Monitoring und Management einer unerbittlichen fibrosierenden Erkrankung
Die idiopathische Lungenfibrose (IPF) ist eine fibrosierende interstitielle Lungenerkrankung, die definitionsgemäß progredient verläuft. Das Fortschreiten der IPF spiegelt sich in der zunehmenden Verschlechterung der Lungenfunktion, der Dyspnoe, der Belastungskapazität und der gesundheitsbezogenen Lebensqualität wider. Kurzfristig ist es nicht möglich, den Krankheitsverlauf bei einem einzelnen Patienten vorherzusagen. Eine Phase relativer Stabilisierung der forcierten Vitalkapazität (FVC) bedeutet nicht, dass die FVC auch in Zukunft stabil bleibt. Eine engmaschige Überwachung mit multiplen Instrumenten, nicht nur Lungenfunktionstests, ist wichtig, um den Krankheitsverlauf individuell zu erfassen und sicherzustellen, dass jedem Patienten eine angemessene Versorgung angeboten wird. Optimales IPF-Management beruht auf einem mehrdimensionalen Vorgehen, das sowohl pharmakologische Therapie zur Verlangsamung der respiratorischen Verschlechterung als auch supportive Maßnahmen zur Aufrechterhaltung der Lebensqualität umfasst.
- 7 April 2020
- Published by S. Karger AG in Kompass Pneumologie
- Vol. 8 (2) , 68-75
Open AccessIdiopathische Lungenfibrose: Best Practices für das Monitoring und Management einer unerbittlichen fibrosierenden Erkrankung
Die idiopathische Lungenfibrose (IPF) ist eine fibrosierende interstitielle Lungenerkrankung, die definitionsgemäß progredient verläuft. Das Fortschreiten der IPF spiegelt sich in der zunehmenden Verschlechterung der Lungenfunktion, der Dyspnoe, der Belastungskapazität und der gesundheitsbezogenen Lebensqualität wider. Kurzfristig ist es nicht möglich, den Krankheitsverlauf bei einem einzelnen Patienten vorherzusagen. Eine Phase relativer Stabilisierung der forcierten Vitalkapazität (FVC) bedeutet nicht, dass die FVC auch in Zukunft stabil bleibt. Eine engmaschige Überwachung mit multiplen Instrumenten, nicht nur Lungenfunktionstests, ist wichtig, um den Krankheitsverlauf individuell zu erfassen und sicherzustellen, dass jedem Patienten eine angemessene Versorgung angeboten wird. Optimales IPF-Management beruht auf einem mehrdimensionalen Vorgehen, das sowohl pharmakologische Therapie zur Verlangsamung der respiratorischen Verschlechterung als auch supportive Maßnahmen zur Aufrechterhaltung der Lebensqualität umfasst.
- Open Access
- 7 April 2020
- Published by S. Karger AG in Kompass Pneumologie
- Vol. 8 (2) , 93-95
Steckbrief Forschung
- 7 April 2020
- Published by S. Karger AG in Kompass Pneumologie
- Vol. 8 (2) , 93-95
Open AccessSteckbrief Forschung